Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Camez

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The British Journal of Dermatology|December 1, 2007
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisD Revicki, M K Willian, J-H Saurat, et al.
American Journal of Hematology|May 1, 1995
Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolismF Bridey, M Dreyfus, F Parent, et al.
Thrombosis and Haemostasis|May 1, 1994
A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosisF Schiele, A Vuillemenot, P Kramarz, et al.
The British Journal of Dermatology|December 1, 2007
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)J-H Saurat, G Stingl, L Dubertret, et al.
Thrombosis and Haemostasis|May 1, 1997
Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study GroupF Schiele, F Lindgaerde, H Eriksson, et al.
Journal of the American College of Cardiology|October 16, 1999
Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trialK L Neuhaus, G P Molhoek, U Zeymer, et al.
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The British Journal of Dermatology|December 1, 2007
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisD Revicki, M K Willian, J-H Saurat, et al.
American Journal of Hematology|May 1, 1995
Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolismF Bridey, M Dreyfus, F Parent, et al.
Thrombosis and Haemostasis|May 1, 1994
A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosisF Schiele, A Vuillemenot, P Kramarz, et al.
The British Journal of Dermatology|December 1, 2007
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)J-H Saurat, G Stingl, L Dubertret, et al.
Thrombosis and Haemostasis|May 1, 1997
Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study GroupF Schiele, F Lindgaerde, H Eriksson, et al.
Journal of the American College of Cardiology|October 16, 1999
Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trialK L Neuhaus, G P Molhoek, U Zeymer, et al.
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Pageof 2